VTGN VTGN

VistaGen Therapeutics Stock Price

0.1563
-0.0187 (-10.69%)
Upgrade to Real-Time
Afterhours (Closed)
0.1563
Volume 20,718,880
Bid Price 0.15
Ask Price 0.1575
News (1)
Day High 0.167

Low
0.1388

52 Week Range

High
3.26

Day Low 0.1504
Company Name Stock Ticker Symbol Market Type
VistaGen Therapeutics Inc VTGN NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.0187 -10.69% 0.1563 00:00:10
Open Price Low Price High Price Close Price Prev Close
0.1657 0.1504 0.167 0.1574 0.175
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
15,837 20,718,880 $ 0.1577809 $ 3,269,044 - 0.1388 - 3.26
Last Trade Time Type Quantity Stock Price Currency
19:57:38 formt 7,000 $ 0.1563 USD

Period:

Draw Mode:

VistaGen Therapeutics Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 32.30M 206.64M 206.42M $ 1.11M $ - -0.25 -0.70
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - 155.00k 0.30%

more financials information »

VistaGen Therapeutics News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical VTGN Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week0.150.18750.14810.165520417,074,8370.00634.2%
1 Month0.90851.070.13880.174585526,000,024-0.7522-82.8%
3 Months1.141.220.13880.24103189,935,944-0.9837-86.29%
6 Months1.501.790.13880.39806685,362,263-1.34-89.58%
1 Year2.743.260.13880.73983573,250,051-2.58-94.3%
3 Years0.49593.550.101.242,170,147-0.3396-68.48%
5 Years1.723.550.101.271,546,532-1.56-90.91%

VistaGen Therapeutics Description

VistaGen Therapeutics Inc is a biotechnology firm. The company is in its clinical stage and engaged in developing and commercializing product candidates for patients with diseases and disorders involving the central nervous system. Its lead product candidate, AV-101, is an orally available prodrug candidate in Phase II development, initially for the adjunctive treatment of a major depressive disorder in patients with an inadequate response to standard antidepressants. The PH94B is a novel neuroactive nasal spray with therapeutic potential in a wide range of indications involving anxiety or phobia; PH10 is an odorless, fast-acting synthetic neurosteroid for neuropsychiatric indications involving depression.


Your Recent History
NASDAQ
VTGN
VistaGen T..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to InvestorsHub
Register Now